Title:Cell Surface Markers and their Targeted Drugs in Breast Cancer
Volume: 23
Issue: 5
Author(s): Yufei Ma, Weidong Li, Kai Ma, Tianyun Wang*Huigen Feng*
Affiliation:
- International Joint
Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University,
Xinxiang, 453003, China
- School of Life Science and Technology, Xinxiang Medical University, Xinxiang, 453003, China
Keywords:
Breast cancer, cell surface markers, targeted therapy, monoclonal antibodies, small molecule inhibitors, drugs.
Abstract: Breast cancer is the most common cancer affecting women's health, and its incidence rate
is continuously increasing. With the development of immunohistochemistry and gene expression microarray
technology, the study on breast cancer has gradually advanced, contributing to the development
of targeted therapy for breast cancer. At present, the popular breast cancer cell surface markers
includeG protein-coupled estrogen receptor 1 (GPER-1), human epidermal growth factor receptor 2
(HER-2), epidermal growth factor receptor (EGFR), c-mesenchymal-epithelial transition factor (CMet),
folate receptor-α (FRα), integrin, programmed death-ligand 1 (PD-L1), trophoblast cell surface
antigen 2 (Trop-2), etc. Targeted drugs for breast cancer cell surface markers mainly include antibody
drugs and small molecule inhibitor drugs, which exert anti-tumor activity by targeting receptors or
ligands. This review summarizes the surface markers of breast cancer cells and their targeted drugs,
hoping to provide new ideas for breast cancer targeted therapy.